Home › Funds › Rosalind Advisors, Inc. › XERS
Rosalind Advisors, Inc. position in XERS
XERIS BIOPHARMA HOLDINGS INC · Health Care
Rosalind Advisors, Inc. reported holding 2,908,981 shares of XERS (XERIS BIOPHARMA HOLDINGS INC) in its Q2 2026 13F filing — a position valued at US$23.0M, representing 8.56% of its reported portfolio and ranking #3 among its reported holdings. Rosalind Advisors, Inc. has disclosed XERS holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Rosalind Advisors, Inc.'s XERS position evolved
Rosalind Advisors, Inc. first disclosed a stake in XERS in Q4 2023 at 3,543,685 shares (US$8.3M). The position peaked in Q2 2026 at 2,908,981 shares, worth US$23.0M. Across 11 filings, Rosalind Advisors, Inc. increased the stake 3 time(s), trimmed it 5 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 2,908,981 shares valued at US$23.0M — a reduction of -322,719 shares quarter over quarter.. Notable position changes include a 53% increase in Q1 2026 (shares rose 37% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 3.54M | $8.33M | New |
| Q1 2024 | 2.82M | $6.23M | Reduce |
| Q2 2024 | 3.12M | $7.02M | Add |
| Q3 2024 | 3.10M | $8.85M | Hold |
| Q4 2024 | 3.10M | $10.53M | Hold |
| Q1 2025 | 2.50M | $13.70M | Reduce |
| Q2 2025 | 2.16M | $10.07M | Reduce |
| Q3 2025 | 1.80M | $14.62M | Reduce |
| Q4 2025 | 2.11M | $16.58M | Add |
| Q1 2026 | 3.23M | $18.74M | Add |
| Q2 2026 | 2.91M | $23.04M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About XERS and 13F data
XERS (XERIS BIOPHARMA HOLDINGS INC) is a Health Care company. 52 other funds we track also report a position in XERS — the largest reported positions include CAPSTONE INVESTMENT ADVISORS, LLC (US$62.6M), Polar Asset Management Partners Inc. (US$28.8M), Parkman Healthcare Partners LLC (US$14.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding XERS
- CAPSTONE INVESTMENT ADVISORS, LLC 23.07M sh · $62.64M · Q2 2026
- Polar Asset Management Partners Inc. 10.50M sh · $28.80M · Q2 2026
- Parkman Healthcare Partners LLC 1.81M sh · $14.32M · Q2 2026
- Vilga Financial Planning LLC 1.06M sh · $10.13M · Q3 2026
- Ishara Investments LP 1.23M sh · $9.74M · Q2 2026
- Knott David M Jr 1.06M sh · $8.40M · Q2 2026
- ESSEX INVESTMENT MANAGEMENT CO LLC 693.26K sh · $6.63M · Q3 2026
More on Rosalind Advisors, Inc.
FAQ
How long has Rosalind Advisors, Inc. held XERS?
Rosalind Advisors, Inc. has disclosed XERS holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
What is Rosalind Advisors, Inc.'s current position in XERS?
As of Q2 2026, Rosalind Advisors, Inc. holds 2.91M shares of XERS (XERIS BIOPHARMA HOLDINGS INC), valued at $23.04M, representing 8.56% of its reported portfolio and ranking #3.
Has Rosalind Advisors, Inc. been buying or selling XERS?
In the latest 13F filing (Q2 2026), Rosalind Advisors, Inc. reduced its position in XERS. The position peaked in Q2 2026 at 2.91M shares.
Which other funds hold XERS?
Other major institutional holders of XERS include CAPSTONE INVESTMENT ADVISORS, LLC, Polar Asset Management Partners Inc., Parkman Healthcare Partners LLC, among 52 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.